Print
Email
Print Edition Stories
Funding drugs for rare diseases
Companies born in the recession
Drug developer CombinatoRx Inc. narrowed its loss in the third quarter on aggressive cost cutting that resulted in a 36 percent reduction in its workforce.
The Cambridge-based company said the move to conserve cash should enable it to continue as a going concern — without any additional equity financing — into 2012.
Nonetheless, CombinatoRx’s (Nasdaq: CRXX) efforts to reduce its cash burn have dramatically affected its research and development budget — a key line item for a company whose future depends on the discovery and commercialization of new drug therapies and related technologies.
CombinatoRx’s cash and cash equivalents totaled $22.2 million as of Sept. 30, down from the company’s June 30 total of $30.6 million. CombinatoRx had $43.7 million in cash on its books as of Dec. 31.
R&D costs totaled $4.9 million in the three-month span, down 65 percent from the $13.8 million spent a year earlier. Year-to-date through Sept. 30, R&D costs totaled $18.2 million, compared with $45.5 million in 2008’s corresponding period.
With $2.7 million in revenue in the third quarter, CombinatoRx booked a net loss of $8.3 million. In 2008, third quarter revenue was $3 million and the company’s net loss was $14.4 million.
CombinatoRx primarily works with partners to discover new therapies using combinations of preexisting drugs and life sciences technologies.
Comments
If you are commenting using a Facebook account, your profile information may be displayed with your comment depending on your privacy settings. By leaving the 'Post to Facebook' box selected, your comment will be published to your Facebook profile in addition to the space below.
RSS Feeds
